Security record · archived quarter
RNAM
Avidity Biosciences Inc · Healthcare · Biotechnology
11Tracked holders
—Δ holders
22.12MShares held
$903.80MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 10.92M | — | $445.94M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 3.80M | — | $155.31M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 3 | Adage Capital Partners ✦ | 3.40M | — | $138.77M | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.26M | — | $92.20M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 739.04K | — | $30.19M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 377.40K | — | $15.42M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 225.75K | — | $9.22M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 160.78K | — | $6.57M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 125.38K | — | $5.12M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 111.77K | — | $4.57M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 12.04K | — | $491,916 | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 8.00K shares, $236,160 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API